Advisory Committee on Immunization Practices (ACIP), 5842 [E9-2164]
Download as PDF
<![CDATA[
dwashington3 on PROD1PC60 with NOTICES
5842
Federal Register / Vol. 74, No. 20 / Monday, February 2, 2009 / Notices
August 3, 2001, renewed at appropriate
intervals, and will expire on August 3,
2009.
Purpose: This Advisory Board is
charged with (a) Providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at
any Department of Energy facility who
were exposed to radiation but for whom
it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters to be Discussed: The agenda
for the Advisory Board meeting
includes: NIOSH Program Status
Update; NIOSH and Department of
Energy (DOE) Security Plans;
Department of Labor (DOL) Update;
Special Exposure Cohort (SEC) Petitions
for: Los Alamos National Laboratory,
Westinghouse Atomic Power
Development, Tyson Valley Powder
Farm, General Steel Industries, Hood
Building (Massachusetts Institute of
Technology), and Blockson Chemical;
SC&A New Technical Support Contract;
Special Exposure Cohort (SEC) Petition
Status Updates; Science Update; Work
Group reports; Subcommittee on Dose
Reconstruction Reviews Report;
Subcommittee on Procedures Reviews
and Board Future Plans and Meetings.
The agenda is subject to change as
priorities dictate.
In the event an individual cannot
attend, written comments may be
submitted according to the policy
provided below. Any written comments
received will be provided at the meeting
and should be submitted to the contact
person below well in advance of the
meeting.
Policy on Redaction of Board Meeting
Transcripts (Public Comment), (1) If a
person making a comment gives his or
her name, no attempt will be made to
redact that name. (2) NIOSH will take
reasonable steps to ensure that
individuals making public comment are
aware of the fact that their comments
(including their name, if provided) will
appear in a transcript of the meeting
posted on a public Web site. Such
reasonable steps include: (a) A
statement read at the start of each public
comment period stating that transcripts
will be posted and names of speakers
will not be redacted; (b) A printed copy
of the statement mentioned in (a) above
will be displayed on the table where
VerDate Nov<24>2008
15:03 Jan 30, 2009
Jkt 217001
individuals sign up to make public
comment; (c) A statement such as
outlined in (a) above will also appear
with the agenda for a Board Meeting
when it is posted on the NIOSH Web
site; (d) A statement such as in (a) above
will appear in the Federal Register
Notice that announces Board and
Subcommittee meetings. (3) If an
individual in making a statement
reveals personal information (e.g.,
medical information) about themselves
that information will not usually be
redacted. The NIOSH FOIA coordinator
will, however, review such revelations
in accordance with the Freedom of
Information Act and the Federal
Advisory Committee Act and if deemed
appropriate, will redact such
information. (4) All disclosures of
information concerning third parties
will be redacted. (5) If it comes to the
attention of the DFO that an individual
wishes to share information with the
Board but objects to doing so in a public
forum, the DFO will work with that
individual, in accordance with the
Federal Advisory Committee Act, to
find a way that the Board can hear such
comments.
CONTACT PERSON FOR MORE INFORMATION:
Theodore Katz, M.P.A., Executive
Secretary, NIOSH, CDC, 1600 Clifton
Road, MS E–20, Atlanta, GA 30333,
Telephone (513) 533–6800, Toll Free 1
(800) CDC–INFO, E-mail ocas@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: January 22, 2009.
Lorenzo J. Falgiano,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E9–2165 Filed 1–30–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices (ACIP)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Times and Dates:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
8 a.m.–5 p.m., February 25, 2009.
8 a.m.–5 p.m., February 26, 2009.
Place: Centers for Disease Control and
Prevention, Tom Harkin Global
Communications Center, 1600 Clifton
Road, NE., Building 19, Kent ‘‘Oz’’
Nelson Auditorium, Atlanta, Georgia
30333.
Status: Open to the public, limited
only by the space available.
Purpose: The committee is charged
with advising the Director, CDC, on the
appropriate uses of immunizing agents.
In addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for
administration to vaccine-eligible
children through the Vaccines for
Children (VFC) program, along with
schedules regarding the appropriate
periodicity, dosage, and
contraindications applicable to the
vaccines.
Matters to be Discussed: The agenda
will include discussions on Anthrax;
Hepatitis Vaccines; Measles, Mumps
and Rubella; Influenza Vaccine;
Pneumococcal Vaccines; Rabies
Vaccine; General Recommendations;
Human Papillomavirus Vaccines;
Herpes Zoster; Meningococcal Vaccine;
MMRV Vaccine Safety; Pertussis; Polio
Vaccine; Vaccine Safety; Vaccine
Supply; Vaccination of Immigrants and
refugees; Yellow Fever. Agenda items
are subject to change as priorities
dictate.
Contact Person for More Information:
Antonette Hill, Immunization Services
Division, National Center for
Immunization and Respiratory Diseases,
CDC, 1600 Clifton Road, NE., (E–05),
Atlanta, Georgia 30333, telephone 404/
639–8836, fax 404/639–8905.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: January 22, 2009.
Lorenzo J. Falgiano,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E9–2164 Filed 1–30–09; 8:45 am]
BILLING CODE 4160–18–P
E:\FR\FM\02FEN1.SGM
02FEN1
]]>Agencies
[Federal Register Volume 74, Number 20 (Monday, February 2, 2009)]
[Notices]
[Page 5842]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-2164]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices (ACIP)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
committee:
Times and Dates:
8 a.m.-5 p.m., February 25, 2009.
8 a.m.-5 p.m., February 26, 2009.
Place: Centers for Disease Control and Prevention, Tom Harkin
Global Communications Center, 1600 Clifton Road, NE., Building 19, Kent
``Oz'' Nelson Auditorium, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
Purpose: The committee is charged with advising the Director, CDC,
on the appropriate uses of immunizing agents. In addition, under 42
U.S.C. 1396s, the committee is mandated to establish and periodically
review and, as appropriate, revise the list of vaccines for
administration to vaccine-eligible children through the Vaccines for
Children (VFC) program, along with schedules regarding the appropriate
periodicity, dosage, and contraindications applicable to the vaccines.
Matters to be Discussed: The agenda will include discussions on
Anthrax; Hepatitis Vaccines; Measles, Mumps and Rubella; Influenza
Vaccine; Pneumococcal Vaccines; Rabies Vaccine; General
Recommendations; Human Papillomavirus Vaccines; Herpes Zoster;
Meningococcal Vaccine; MMRV Vaccine Safety; Pertussis; Polio Vaccine;
Vaccine Safety; Vaccine Supply; Vaccination of Immigrants and refugees;
Yellow Fever. Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Antonette Hill, Immunization
Services Division, National Center for Immunization and Respiratory
Diseases, CDC, 1600 Clifton Road, NE., (E-05), Atlanta, Georgia 30333,
telephone 404/639-8836, fax 404/639-8905.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both CDC and the Agency for Toxic Substances and Disease Registry.
Dated: January 22, 2009.
Lorenzo J. Falgiano,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. E9-2164 Filed 1-30-09; 8:45 am]
BILLING CODE 4160-18-P
